Wet Macular Degeneration

SAN FRANCISCO — Patients with wet age-related macular degeneration and diabetic macular edema who received viscous topical anesthetics before anti-VEGF injections were at increased risk for development of endophthalmitis, according to a speaker.

An intravitreal dose of ADVM-022, a gene therapy designed for long-term VEGF suppression via the expression of aflibercept, resulted in no anti-VEGF rescue injections for patients with wet age-related macular degeneration, according to 24-week clinical data in the OPTIC phase 1 clinical trial.

PARIS — Partnering with Fight for Sight, the European Society of Retina Specialists will award a 2 million euros grant to a research project addressing the best treatment option for submacular hemorrhage secondary to wet age-related macular degeneration.

RGX-314, Regenxbio’s gene therapy using NAV vectors for AAV-mediated antibody delivery, has shown positive phase 1/2a results in patients with wet age-related macular degeneration, continuing to be well tolerated across five dose cohorts, according to a press release.

CHICAGO — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed the progression of geographic atrophy was mostly unchanged in trial participants, according to a speaker here.

The European Medicines Agency has validated the marketing authorization application for abicipar, Molecular Partners announced.

CHICAGO — At the American Society of Retina Specialists meeting, David S. Boyer, MD, discusses his presentation comparing anatomical and visual results from the HARBOR study of ranibizumab for the treatment of neovascular age-related macular degeneration.